Department of Oral and Maxillofacial Surgery, Center for Translational Medicine, Precision Medicine Institute, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Oncology Department, Chinese PLA General Hospital, Beijing, China.
Oral Dis. 2024 Apr;30(3):1100-1113. doi: 10.1111/odi.14596. Epub 2023 May 15.
Head and neck squamous cell carcinoma (HNSCC) is the most common type of malignancy in the head and neck region worldwide. The therapeutic strategies for HNSCC remain unsatisfying and limited. Here, we found a population of resistant Bmi1-expressing cells in the presence of cetuximab treatment and reported a novel role of SRY-box transcription factor 18 (SOX18), a member of the SOX family, in promoting HNSCC resistance to cetuximab. This study aimed to investigate the regulatory mechanism of Sox18 in Bmi1-positive cells and to search for better therapeutic targets.
We successfully obtained Bmi1, Rosa, and Rosa mice and identified Bmi1-expressing cells through lineage tracing. SOX18 expression in HNSCC and normal tissues was analyzed by immunohistochemistry, colocalization of Sox18, and Bmi1-expressing cells was analyzed by immunofluorescence, and SOX18 expression in SCC9 cell lines was quantified by western blotting and quantitative real-time PCR. The investigation of the mechanism of SOX18-mediated cetuximab resistance in Bmi1-positive cells was based on the analysis of single-cell RNA-seq data obtained from the Gene Expression Omnibus (GEO) database. Western blotting was performed to verify the results obtained from the single-cell RNA-seq analysis.
In our study, we demonstrated that Bmi1-expressing cells were resistant to cetuximab treatment and that depletion of Bmi1-expressing cells improved cetuximab efficacy in HNSCC. We then discovered that Sox18 mediated the stem cell-like properties of Bmi1-expressing cells and promoted cellular cetuximab resistance through an oxidative phosphorylation pathway. There was a significant downregulation of key genes in the oxidative phosphorylation pathway in Sox18 knockout cell lines.
Taken together, the findings of our study suggest that Sox18 mediates the resistance of Bmi1-expressing cells to cetuximab in HNSCC via the oxidative phosphorylation pathway.
头颈部鳞状细胞癌(HNSCC)是全球头颈部最常见的恶性肿瘤。HNSCC 的治疗策略仍然不尽如人意且有限。在这里,我们在西妥昔单抗治疗存在的情况下发现了一群抵抗性 Bmi1 表达细胞,并报道了 SOX 家族成员之一的性别决定区 Y 框转录因子 18(SOX18)在促进 HNSCC 对西妥昔单抗耐药中的新作用。本研究旨在探讨 Sox18 在 Bmi1 阳性细胞中的调控机制,并寻找更好的治疗靶点。
我们成功获得了 Bmi1、Rosa 和 Rosa 小鼠,并通过谱系追踪鉴定了 Bmi1 表达细胞。通过免疫组织化学分析 HNSCC 和正常组织中的 SOX18 表达,通过免疫荧光分析 Sox18 与 Bmi1 表达细胞的共定位,通过 Western blot 和定量实时 PCR 定量分析 SCC9 细胞系中的 SOX18 表达。基于从基因表达综合(GEO)数据库获得的单细胞 RNA-seq 数据分析,研究了 SOX18 介导的 Bmi1 阳性细胞中对西妥昔单抗耐药的机制。通过 Western blot 验证了单细胞 RNA-seq 分析获得的结果。
在我们的研究中,我们证明 Bmi1 表达细胞对西妥昔单抗治疗具有抗性,并且耗尽 Bmi1 表达细胞可提高 HNSCC 中西妥昔单抗的疗效。然后,我们发现 Sox18 介导了 Bmi1 表达细胞的干细胞样特性,并通过氧化磷酸化途径促进了细胞对西妥昔单抗的耐药性。在 Sox18 敲除细胞系中,氧化磷酸化途径中的关键基因显著下调。
综上所述,本研究结果表明 Sox18 通过氧化磷酸化途径介导 Bmi1 表达细胞对 HNSCC 中西妥昔单抗的耐药性。